[摘 要] 目的：评价厄洛替尼联合白蛋白紫杉醇与卡铂治疗EGFR驱动基因阳性NSCLC患者的临床疗效及安全性。方法： 选取2019年5月至2021年6月于西京医院肿瘤科接受治疗的80例EGFR驱动基因阳性NSCLC患者作为研究对象，按照治疗方法分为研究组（n = 38）及对照组（n = 42），两组患者均予厄洛替尼靶向治疗，研究组患者同时联合白蛋白紫杉醇与卡铂化疗。比较两组患者的治疗疗效（客观缓解率、疾病控制率）、免疫功能[CD3+、CD4+、CD8+、CD4+/CD8+、自然杀伤（NK）细胞]、生存状况[3年生存率、总生存期（OS）和无进展生存期（PFS）、卡氏功能状态（KPS）评分]、肿瘤标志物水平[癌胚抗原（CEA）、细胞角蛋白片段19（CYFRA21-1）、血管内皮生长因子（VEGF）]及不良反应发生率。结果： 研究组疾病控制率为89.47%，高于对照组的42.86%，差异有统计学意义（P < 0.05）；研究组客观缓解率为36.84%高于对照组的23.81%，但差异无统计学意义（P > 0.05）。治疗后，研究组CD3+、CD4+、NK细胞、CD4+/CD8+水平均高于对照组，而CD8+水平低于对照组（均P < 0.05）；两组3年生存率差异无统计学意义（P > 0.05）；研究组OS、PFS均长于对照组（均P < 0.05），且KPS评分高于对照组（P < 0.05）；研究组的CEA、CYFRA21-1、VEGF水平均低于对照组（均P < 0.05）；研究组骨髓抑制发生率高于对照组（均P < 0.05）。结论： 厄洛替尼靶向联合白蛋白紫杉醇与卡铂治疗EGFR驱动基因阳性NSCLC，治疗效果良好，可减少免疫功能损伤，延长晚期NSCLC患者PFS，提升其生活质量，且安全性良好。

[Abstract] Objective: To investigate the effects of over-expressing VASH1 on the malignant biological behaviors of human colorectal cancer cells. Methods: Lentivirus was packaged and transfected into human colorectal cancer cells SW680 and SW620 to construct an over-expressed VASH1 cell line, the untransfected cells were used as control. qPCR experiment and WB experiment were used to detect the over-expression effect of VASH1. The effects of VASH1 over-expressed on microangiogenesis, proliferation, colony formation and migration of colorectal cancer cells were detected respectively by tubule formation, CCK-8 assay, soft agar assay, Transwell assay and Wound healing assay in vitro. In addition, tumor growth and lung metastasis were detected in NOD-SCID mice subcutaneously injected with VASH1-overexpressing SW620 cells. Results: Successfully constructed SW480 and SW620 cells over-expressing VASH1. Compared with the control group, the abilities of microangiogenesis, proliferation, colony forming and migration were significantly reduced in colorectal cancer cells over-expressing VASH1 (P<0.05) in vitro. The abilities of subcutaneous tumor growth and lung metastasis of colorectal cancer cells over-expressing VASH1 were also significantly reduced (P<0.05) in vivo. Conclusion: Over-expression of VASH1 can suppress the malignant biological behaviors of human colorectal cancer cells.

Intracardiac thrombus is a rare complication of Antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE). Its treatment is extremely tough and requires a multidisciplinary approach. We reported a case of SLE with intracardiac thrombus and pulmonary embolism. The patient was complicated with hemoptysis and kidney injury，and had a high risk of sudden death from incidental thrombus shedding off. In the state of thrombosis and hemorrhage，the management of anticoagulation and the evaluation and treatment of the primary disease complicated with infection are challenging. The multidisciplinary collaboration helped us to create a more favorable surgical condition while controlling SLE aggressively. After surgical treatment at the proper time，the outcome of the patient was satisfying.